Board Of Trustees Of The Leland Stanford Junior University Unicycive Therapeutics, Inc. Transaction History

Board Of Trustees Of The Leland Stanford Junior University

$1.17 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$0.57 - $0.9 $105,201 - $166,107	-184,564 Reduced 74.55%	63,019 $37,000
Q3 2021 Nov 12, 2021	BUY	$2.47 - $5.85 $611,530 - $1.45 Million	247,583 New	247,583 $700,000

Others Institutions Holding UNCY

# of Institutions

Shares Held

46.8M

Call Options Held

Put Options Held

Octagon Capital Advisors LP New York, NY

8.56M
Shares

$5.99 Million
0.85% of portfolio
Great Point Partners LLC Greenwich, CT

8.56M
Shares

$5.99 Million
1.62% of portfolio
Logos Global Management LP San Francisco, CA

5.08M
Shares

$3.56 Million
0.28% of portfolio
Walleye Capital LLC Plymouth, MN

5M
Shares

$3.5 Million
0.0% of portfolio
Vivo Capital, LLC Palo Alto, CA

4.47M
Shares

$3.13 Million
0.27% of portfolio

View Full List

About Unicycive Therapeutics, Inc.

Ticker UNCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,052,500
Market Cap $10.5M
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...

More about UNCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Board Of Trustees Of The Leland Stanford Junior University, based on Form 13F filings with the SEC.

News

Stay updated on Board Of Trustees Of The Leland Stanford Junior University with notifications on news.

Account